243 The role of the MR 7 Supplemental Table 3. Patients’ characteristics for survival analyses Patients Number 131 Median follow up (95%-CI) months 26.1 (23.8-28.4) Reverse Kaplan Meier Events Induction failure n (%) 1 (0.8) Relapse n (%) 22 (16.8) Secondary malignancy n (%) 2 (1.5) Death n (%) 8 (6.1) NB: all second events n (%) Age at diagnosis years Median (range) 5 (1-18) 1-4 63 (48.1) 5-9 24 (18.3) 10-14 24 (18.3) 15-18 20 (15.3) Sex Girl 50 (38.2) Boy 81 (61.8) ALL subclass B-cell ALL 114 (87) T-cell ALL 17 (13) Cytogenetic subtype ETV6-RUNX1 28 (21.4) High hyperdiploid 35 (26.7) BCR-ABL 3 (2.3) DUX4 3 (2.3) Down syndrome 3 (2.3) iAMP21 8 (6.1) TCF3 rearranged 5 (3.8) T-cell ALL 17 (13) Other/NOS 29 (22.1) CNS involvement No 122 (93.1) Yes 4 (3.1) Unknown 5 (3.8) Leucocytes at diagnosis Median (range) 11.2 (0.8-705) <10 59 (45.0) 10-25 29 (22.1) 25-50 14 (10.7) 50-100 15 (11.5) >100 14 (10.7)
RkJQdWJsaXNoZXIy MTk4NDMw